A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain [PDF]
BMC Urology, 2018 Background Persistence on-treatment with antimuscarinics in patients with overactive bladder (OAB) is reported to be sub-optimal. This retrospective, longitudinal, observational cohort study assessed treatment persistence with β3-adrenoceptor agonists (i.
Jameel Nazir +6 more
doaj +3 more sources
PLoS ONE, 2019 BackgroundWe aim to examine the trend in the use of antimuscarinics and off-label alpha-adrenergic blockers for treatment of lower urinary tract symptoms (LUTS) in a Taiwanese Women Cohort between 2007 and 2012.MethodsThis population-based National ...
Yu-Hua Lin +6 more
doaj +2 more sources
Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?
Journal of Urological Surgery, 2019 Oral pharmacotherapy constitutes second-line treatment for overactive bladder (OAB) after lifestyle modifications, bladder retraining, and pelvic floor muscle exercises. Antimuscarinics have an established role in the treatment of OAB.
Ömer Acar +2 more
doaj +2 more sources
An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder [PDF]
Advances in Urology, 2011 Overactive bladder is a common and bothersome condition. Antimuscarinic agents, as a class, are the cornerstone of medical treatment of overactive bladder. They offer significant improvements in symptoms and patients’ quality of life. Antimuscarinics are
Anastasios Athanasopoulos +1 more
doaj +2 more sources
Urological Science, 2018 Objectives: Although antimuscarinic drugs are considered the gold standard for overactive bladder (OAB), high discontinuation rates have been observed. However, no information is known about this in Taiwan.
Hao-Wei Chen +9 more
doaj +2 more sources
Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases. [PDF]
PLoS ONE, 2018 For managing overactive bladder (OAB), mirabegron, a β3 adrenergic receptor agonist, is typically used as second-line pharmacotherapy after antimuscarinics.
E Vonesh +6 more
doaj +2 more sources
Lower Urinary Tract Symptoms as Diagnostic Clues in Parkinsonism: A Practical Framework for Neurologists. [PDF]
Mov Disord Clin PractAbstract Background Lower urinary tract symptoms (LUTS) are among the most prevalent nonmotor complaints across the parkinsonian spectrum, yet they remain underutilized as diagnostic and management signals in neurology practice. Although prior reviews have characterized disease‐specific patterns of urinary dysfunction, and recent guidelines address ...
Anis S, Anis O, Lenka A, Siddiqui JH.
europepmc +2 more sources
β3-Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First-Line Therapy. [PDF]
Neurourol UrodynABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Fishberg SE, Matta R.
europepmc +2 more sources
Research and Reports in Urology, 2012 Alka A Bhide, G Alessandro Digesu, Ruwan Fernando, Vik KhullarDepartment of Urogynaecology, St Mary's Hospital, London, United KingdomAbstract: Overactive bladder is a common condition that significantly impacts overall quality of life ...
Bhide AB +3 more
doaj +1 more source
"What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD"-Pro Botox. [PDF]
Neurourol UrodynABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Furlan V, Kobayashi A, Sadeghi Z.
europepmc +2 more sources